Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- No Plan to Respond to MHLW Task Force’s Proposal on Vaccine, Blood Product Industries: JPMA
October 21, 2016
- Keidanren Wades into Pricy Med Debate, Calls for Quick Price Review
October 17, 2016
- Govt and Industry Should Generate Ideas Together: EFPIA Japan Chief
October 7, 2016
- Value of Pharmaceutical Innovation Should Be Fully Recognized: PhRMA CEO
September 30, 2016
- Generic Use Rate at 60.1% in April-June: JGA
September 30, 2016
- Japan Wholesaler Chief Suzuki to Become IFPW Vice Chairman
September 16, 2016
- Japan Needs Listing Rule Conditional on Possible Ad-Hoc Re-Pricing: Kono
September 7, 2016
- Kenporen’s Kono Pushes for “Huge Seller” Re-Pricing for Opdivo before 2018
September 7, 2016
- Hodanren Demands Ad-Hoc Re-Pricing for Opdivo
September 7, 2016
- Economists, Industry and Regulatory Officials Talk over Pricy Med Issue at JPMA Seminar
September 6, 2016
- JMA Think Tank Calls for Rewarding Innovation with Subsidies, in Lieu of Pricing
September 1, 2016
- Drug Wholesalers See 8.3% Boost in Sales on Hep C Demand: JPWA
August 17, 2016
- JPMA Calls for Financial Support to Encourage R&D on Treatments for ARIs
August 15, 2016
- Sales Rep Number in Japan Logs Big Drop for 2nd Straight Year: Survey
August 12, 2016
- EFPIA Japan Calls for Relaxation of Japanese Vaccine Regulations: Vaccine Subcommittee Head
August 9, 2016
- NPO Petitions Academic Society to Clarify Reason for Deaths Associated with Xeplion
July 20, 2016
- Japan Biosimilar Association Up and Running with Four Member Firms
July 19, 2016
- JPMA Keen to Defend R&D Tax Credit System
July 8, 2016
- Generic Use Rate at 55.7% in FY2015, Up 3.7 Points: JGA
July 8, 2016
- EFPIA Japan Calls for Diversifying Vaccine Supply Sources to Prepare for Crises
July 7, 2016
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…